CoChat

Preclinical evaluation of a protracted GLP-1/glucagon receptor co-agonist: Translational difficulties and pitfalls

Open access

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Abstract

During recent years combining GLP-1 and glucagon receptor agonism with the purpose of achieving superior weight loss and metabolic control compared to GLP-1 alone has received much attention. The superior efficacy has been shown by several in preclinical models but has been difficult to reproduce in humans. In this paper, we present the pre-clinical evaluation of NN1177, a long-acting GLP-1/glucagon receptor co-agonist previously tested in clinical trials. To further investigate the contribution from the respective receptors, two other co-agonists (NN1151, NN1359) with different GLP-1-to-glucagon receptor ratios were evaluated in parallel. In the process of characterizing NN1177, species differences and pitfalls in traditional pre-clinical evaluation methods were identified, highlighting the translational challenges in predicting the optimal receptor balance in humans. In diet-induced obese (DIO) mice, NN1177 induced a dose-dependent body weight loss, primarily due to loss of fat mass, and improvement in glucose tolerance. In DIO rats, NN1177 induced a comparable total body weight reduction, which was in contrast mainly caused by loss of lean mass, and glucose tolerance was impaired. Furthermore, despite long half-lives of the three co-agonists, glucose control during steady state was seen to depend on compound exposure at time of evaluation. When evaluated at higher compound exposure, glucose tolerance was similarly improved for all three co-agonists, independent of receptor balance. However, at lower compound exposure, glucose tolerance was gradually impaired with higher glucagon receptor preference. In addition, glucose tolerance was found to depend on study duration where the effect of glucagon on glucose control became more evident with time. To conclude, the pharmacodynamic effects at a given GLP-1-to-glucagon ratio differs between species, depends on compound exposure and study length, complicating the identification of an optimally balanced clinical candidate. The present findings could partly explain the low number of clinical successes for this dual agonism.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0264974

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Depiction of compound sequences vs native human GLP-1 and glucagon. The sequences of the GLP-1/glucagon receptor co-agonists (NN1177, NN1151, NN1359) and the GLP-1 reference. Red colour is used to denote amino acids arising from neither the human-glucagon or -GLP-1 sequence. X = 2-aminoisobutyric acid, B = 1-amino-1-cyclobutanecarboxylic acid, Z = 3-(1H-Imidazol-4-yl) propionic acid. The fatty acid containing side-chains are attached to the peptide sequences via the epsilon amine of lysine in positions marked with* (Sidechains used: NN1177; -γGlu-γGlu-Ser-Glu-Ser-γGlu-γGlu-C18 diacid, NN1151; -γGlu-γGlu-ADO-ADO-γGlu-γGlu-C18-diacid, GLP-1 ref.; -γGlu-γGlu-ADO-ADO-γGlu-C18-diacid, NN1359; -ADO-ADO-γGlu-γGlu-C18-diacid. (For full structures see S1 Fig).
Fig 1 Depiction of compound sequences vs native human GLP-1 and glucagon. The sequences of the GLP-1/glucagon receptor co-agonists (NN1177, NN1151, NN1359) and the GLP-1 reference. Red colour is used to denote amino acids arising from neither the human-glucagon or -GLP-1 sequence. X = 2-aminoisobutyric acid, B = 1-amino-1-cyclobutanecarboxylic acid, Z = 3-(1H-Imidazol-4-yl) propionic acid. The fatty acid containing side-chains are attached to the peptide sequences via the epsilon amine of lysine in positions marked with* (Sidechains used: NN1177; -γGlu-γGlu-Ser-Glu-Ser-γGlu-γGlu-C18 diacid, NN1151; -γGlu-γGlu-ADO-ADO-γGlu-γGlu-C18-diacid, GLP-1 ref.; -γGlu-γGlu-ADO-ADO-γGlu-C18-diacid, NN1359; -ADO-ADO-γGlu-γGlu-C18-diacid. (For full structures see S1 Fig).CC BY · PubMed Central
Fig 2 Effect on body weight and food intake in DIO mice. Body weight as percent of baseline in DIO mice with a baseline body weight of 45–50 g (A, B, C) and cumulative food intake in kcals per animal (D, E, F) of the GLP-1/glucagon receptor co-agonists NN1151 (A, D), NN1177 (B, E) and NN1359 (C, F) vs vehicle and the GLP-1 reference compound, following daily s.c. administration in DIO mice (n = 8–20) *p<0.05; **p<0.01; ***p<0.001 vs vehicle; ^^p<0.01, ^^^p<0.001 vs the GLP-1 reference compound as assessed on the last day of treatment. For clarification where hard to differentiate statistical denotations in the figure (D): p<0.05 NN1151 10nmol/kg vs vehicle; p<0.01 GLP-1 ref vs vehicle; (E): p<0.05 GLP-1 ref vs vehicle and NN1177 3nmol/kg vs vehicle; p<0.01 1177 4nmol/kg vs vehicle; p<0.001 NN1177 5nmol/kg vs vehicle; (F): p<0.05 NN1359 3nmol/kg vs vehicle; p<0.01 GLP-1 ref vs vehicle and NN1359 5nmol/kg vs vehicle; p<0.001 NN1359 10nmol/kg vs vehicle and NN1359 30nmol/kg vs vehicle.
Fig 2 Effect on body weight and food intake in DIO mice. Body weight as percent of baseline in DIO mice with a baseline body weight of 45–50 g (A, B, C) and cumulative food intake in kcals per animal (D, E, F) of the GLP-1/glucagon receptor co-agonists NN1151 (A, D), NN1177 (B, E) and NN1359 (C, F) vs vehicle and the GLP-1 reference compound, following daily s.c. administration in DIO mice (n = 8–20) *p<0.05; **p<0.01; ***p<0.001 vs vehicle; ^^p<0.01, ^^^p<0.001 vs the GLP-1 reference compound as assessed on the last day of treatment. For clarification where hard to differentiate statistical denotations in the figure (D): p<0.05 NN1151 10nmol/kg vs vehicle; p<0.01 GLP-1 ref vs vehicle; (E): p<0.05 GLP-1 ref vs vehicle and NN1177 3nmol/kg vs vehicle; p<0.01 1177 4nmol/kg vs vehicle; p<0.001 NN1177 5nmol/kg vs vehicle; (F): p<0.05 NN1359 3nmol/kg vs vehicle; p<0.01 GLP-1 ref vs vehicle and NN1359 5nmol/kg vs vehicle; p<0.001 NN1359 10nmol/kg vs vehicle and NN1359 30nmol/kg vs vehicle.CC BY · PubMed Central
Fig 3 Effect of NN1177 in DIO rats. Body weight as % of baseline in DIO rats with an initial body weight of approximately 600 g (A), accumulated food intake in kcals (B), blood glucose levels during OGTT (C), incremental AUC of blood glucose levels during OGTT (D), and baseline blood glucose levels (E) in DIO rats treated once daily s.c. with vehicle, the GLP-1 reference, the GLP-1/glucagon receptor co-agonist NN1177 or a combination of NN1177 and the GLP-1 reference (n = 10). The oral glucose tolerance test was performed on day 15, 5 h post compound administration, corresponding to Cmax,*p<0.05,**p<0.01, ***p<0.001 vs vehicle; ^^p<0.01 vs GLP-1 reference.
Fig 3 Effect of NN1177 in DIO rats. Body weight as % of baseline in DIO rats with an initial body weight of approximately 600 g (A), accumulated food intake in kcals (B), blood glucose levels during OGTT (C), incremental AUC of blood glucose levels during OGTT (D), and baseline blood glucose levels (E) in DIO rats treated once daily s.c. with vehicle, the GLP-1 reference, the GLP-1/glucagon receptor co-agonist NN1177 or a combination of NN1177 and the GLP-1 reference (n = 10). The oral glucose tolerance test was performed on day 15, 5 h post compound administration, corresponding to Cmax,*p<0.05,**p<0.01, ***p<0.001 vs vehicle; ^^p<0.01 vs GLP-1 reference.CC BY · PubMed Central
Fig 4 Acute glucose control in DIO mice. Blood glucose excursions (A) and incremental AUCs (B) following IPGTT in DIO mice receiving a single dose of vehicle, the GLP-1 reference compound or the GLP-1/glucagon receptor co-agonist NN1177 at 3 or 5 nmol/kg (n = 8–18). Glucose tolerance of NN1177 was evaluated 5 h post administration of compound (Cmax) or 24 h post administration of compound (Cmin). **p<0.01; ***p<0.001 vs vehicle or as indicated; ^^^p<0.001 vs the GLP-1 reference compound.
Fig 4 Acute glucose control in DIO mice. Blood glucose excursions (A) and incremental AUCs (B) following IPGTT in DIO mice receiving a single dose of vehicle, the GLP-1 reference compound or the GLP-1/glucagon receptor co-agonist NN1177 at 3 or 5 nmol/kg (n = 8–18). Glucose tolerance of NN1177 was evaluated 5 h post administration of compound (Cmax) or 24 h post administration of compound (Cmin). **p<0.01; ***p<0.001 vs vehicle or as indicated; ^^^p<0.001 vs the GLP-1 reference compound.CC BY · PubMed Central
Fig 5 Subchronic glucose control in DIO mice. IPGTT in DIO mice treated sub-chronically with vehicle, the GLP-1 reference compound, the GLP-1 glucagon receptor co-agonists NN1151, NN1177 or NN1359. Vehicle-subtracted blood glucose excursions (A, B), corresponding fasted basal blood glucose (C) and derived AUCs of blood glucose during IPGTT (D). Exposure levels during steady state treatment (n = 4) (E) and exposure at t = 210 min vs AUC blood glucose (F). Glucose tolerance of the co-agonists was evaluated in steady state following 3–5 weeks of treatment, 5 h post administration of compound (Cmax) or 24 h post administration of compound (Cmin) respectively (n = 8–28). *p<0.05, ***p<0.001 vs vehicle or as indicated; ^p<0.05, ^^p<0.01, ^^^p<0.001 vs the GLP-1 reference compound.
Fig 5 Subchronic glucose control in DIO mice. IPGTT in DIO mice treated sub-chronically with vehicle, the GLP-1 reference compound, the GLP-1 glucagon receptor co-agonists NN1151, NN1177 or NN1359. Vehicle-subtracted blood glucose excursions (A, B), corresponding fasted basal blood glucose (C) and derived AUCs of blood glucose during IPGTT (D). Exposure levels during steady state treatment (n = 4) (E) and exposure at t = 210 min vs AUC blood glucose (F). Glucose tolerance of the co-agonists was evaluated in steady state following 3–5 weeks of treatment, 5 h post administration of compound (Cmax) or 24 h post administration of compound (Cmin) respectively (n = 8–28). *p<0.05, ***p<0.001 vs vehicle or as indicated; ^p<0.05, ^^p<0.01, ^^^p<0.001 vs the GLP-1 reference compound.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Cited by

See all 40

Metadata

Authors
Simonsen, L., Lau, J., Kruse, T., Guo, T., McGuire, J., Jeppesen, J. F., Niss, K., Sauerberg, P., Raun, K., & Dornonville de la Cour, C.
Affiliations
Novo Nordisk (Denmark) (DK)
Venue
PLOS ONE
Published
2022-03-04
Volume
17
Issue
3
Pages
e0264974
ISSN
1932-6203 (ISSN-L)
OpenAlex
W4214815915
Cited by
36
References
40
Citations by year
2026: 7 · 2025: 7 · 2024: 10 · 2023: 7 · 2022: 5
FWCI
5.37
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Novo Nordisk
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
obesity, weight loss, glucose tolerance, diet-induced obesity, species differences, pharmacodynamics, lean mass loss, fat loss, translational research, study duration
MeSH terms
Glucagon-Like Peptide-1 Receptor, Animals, Blood Glucose, Glucagon, Mice, Obese, Obesity, Weight Loss, Receptors, Glucagon, Mice, Rats, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Preclinical evaluation of a protracted GLP-1/glucagon receptor co-agonist: Translational difficulties and pitfalls. https://app.cochat.ai/papers/10.1371/journal.pone.0264974
The paper
Simonsen, L., Lau, J., Kruse, T., Guo, T., McGuire, J., Jeppesen, J. F., Niss, K., Sauerberg, P., Raun, K., & Dornonville de la Cour, C. (2022). Preclinical evaluation of a protracted GLP-1/glucagon receptor co-agonist: Translational difficulties and pitfalls. PLOS ONE. https://doi.org/10.1371/journal.pone.0264974

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.